Praxis Precision Medicines shares fell 12% in extended trading after its experimental epilepsy drug failed a mid-to-late stage study. The drug, vormatrigine, did not meet its primary goal of reducing monthly seizure frequency in adults with focal onset seizures. The failure forces a reassessment of the clinical program and pauses further enrollment in an ongoing secondary trial.

Vormatrigine Misses Primary Efficacy Goal